With 88 biologics facing exclusivity loss, Stelara biosimilars are under scrutiny as manufacturers compete for market share in autoimmune diseases. Stelara, J&J's top seller in 2024 with $10.4 billion revenue, now faces seven biosimilars mostly priced 80-90% below originator cost. Unlike the Humira biosimilar market, few Stelara competitors adopted dual pricing or secured FDA interchangeability status, though FDA seeks regulatory changes to deem all biosimilars interchangeable eventually. Upcoming launches like Bio-Thera and Hikma's Starjemza may shake the competitive dynamics further.